Diagnostics & Research stocks worldwide, ranked

As of 13 Nov 2026, Australian Clinical Labs (ACL.AX) ranks first in Diagnostics & Research on MoatMap, with a MoatMap Score of 98/100, among 68 companies in 14 countries worth $200M or more that trade $1M or more a day. A research ranking, not investment advice.

The score reads each company's latest yearly results, so when a whole industry is near the top of its cycle, its companies can rank high together.

Live list, follows each night's scores · scores as of ·How we score stocks

The top 25 Diagnostics & Research companies by MoatMap Score

#StockYieldP/EScoreQVMStyle · Activity
1
ACL.AX
Australian Clinical Labs Limited
Australia · $384.6M

Momentum 83: near its 52-week high and outperforming the market over 6 months. Quality 66: strong free cash flow and high gross profitability. Value 65: cheap on free cash flow and cheap on sales.

Yield 4.1%P/E 27.0
98
Score
66
Q
65
V
83
M
Full House
2
603259.SS
WuXi AppTec Co., Ltd.
China · $65.8B

Momentum 81: estimates revised up and above its moving averages. Quality 81: wide operating margins and ROIC in the top 5% of its sector. Value 45: expensive on sales.

Yield 1.4%P/E 16.4
96
Score
81
Q
45
V
81
M
Premium Grower
3
FLRY3.SA
Fleury S.A.
Brazil · $3B

Value 78: a high yield and cheap on free cash flow. Momentum 72: above its moving averages and outperforming the market over 6 months. Quality 59: strong free cash flow but high debt.

Yield 6.5%P/E 14.0
96
Score
59
Q
78
V
72
M
Full HouseDir. sell $839K
4
4694.T
BML, Inc.
Japan · $904.7M

Value 78: cheap on EV/EBITDA and cheap on sales. Quality 68: F-Score 8/9 and interest well covered. Momentum 60: near its 52-week high and estimates revised up.

Yield 3.2%P/E 17.9
96
Score
68
Q
78
V
60
M
Full House
5
BIM.PA
bioMérieux S.A.
France · $11.8B

Quality 74: F-Score 7/9 and strong free cash flow. Momentum 70: estimates revised up and outperforming the market over 6 months. Value 53: mixed.

Yield 1.0%P/E 23.9
92
Score
74
Q
53
V
70
M
Full HouseDir. sell $744K
6
4544.T
H.U. Group Holdings, Inc.
Japan · $1.3B

Value 70: cheap on sales and cheap on EV/EBITDA. Momentum 65: near its 52-week high and outperforming the market over 6 months. Quality 60: F-Score 9/9 and strong free cash flow.

Yield 3.1%P/E 22.6
91
Score
60
Q
70
V
65
M
Full House
7
300685.SZ
Amoy Diagnostics Co., Ltd.
China · $1.1B

Quality 83: a liquid balance sheet and wide operating margins. Momentum 62: estimates revised up and outperforming the market over 6 months. Value 48: mixed.

Yield 2.3%P/E 22.2
90
Score
83
Q
48
V
62
M
Premium GrowerDir. buy $606K
8
VIMIAN.ST
Vimian Group AB (publ)
Sweden · $2.2B

Momentum 79: near its 52-week high and above its moving averages. Quality 60: strong free cash flow and wide operating margins. Value 52: cheap on EV/EBITDA but expensive on P/E.

Yield —P/E 55.3
89
Score
60
Q
52
V
79
M
Full HouseDir. buy $137KDir. sell $790KDeep dive →
9
300244.SZ
Dian Diagnostics Group Co.,Ltd.
China · $2B

Momentum 66: quarterly earnings growing and estimates revised up. Quality 64: F-Score 8/9 and strong free cash flow. Value 61: cheap on free cash flow and cheap on sales.

Yield 1.6%P/E 27.8
89
Score
64
Q
61
V
66
M
Full HouseDir. buy $3KDir. sell $23.6M
10
MEDP
Medpace Holdings, Inc.
United States · $18.7B

Quality 85: ROIC in the top 5% of its sector and high return on equity. Momentum 78: outperforming the market over 6 months and near its 52-week high. Value 26: far above book value.

Yield —P/E 36.3
88
Score
85
Q
26
V
78
M
Premium GrowerDir. sell $230.2MDeep dive →
11
300406.SZ
Beijing Strong Biotechnologies,Inc.
China · $1B

Momentum 67: EPS improving and outperforming the market over 6 months. Quality 64: wide operating margins and a liquid balance sheet. Value 53: cheap on free cash flow.

Yield 2.7%P/E 29.8
84
Score
64
Q
53
V
67
M
Full House
12
ERF.PA
Eurofins Scientific SE
Luxembourg · $16.2B

Momentum 82: near its 52-week high and outperforming the market over 6 months. Quality 55: F-Score 7/9 but a tight balance sheet. Value 45: far above book value.

Yield 0.8%P/E 30.8
83
Score
55
Q
45
V
82
M
Premium GrowerDeep dive →
13
SHL.AX
Sonic Healthcare Limited
Australia · $6.6B

Value 73: a high yield and cheap on sales. Momentum 55: near its 52-week high but estimates cut. Quality 53: a tight balance sheet.

Yield 5.4%P/E 16.3
83
Score
53
Q
73
V
55
M
Full House
14
DGX
Quest Diagnostics Incorporated
United States · $26.7B

Momentum 67: near its 52-week high and outperforming the market over 6 months. Quality 65: F-Score 8/9 and strong free cash flow. Value 48: mixed.

Yield 1.3%P/E 25.5
82
Score
65
Q
48
V
67
M
Premium GrowerDir. sell $17.7M
15
DIA.MI
DiaSorin S.p.A.
Italy · $4.4B

Momentum 70: near its 52-week high and above its moving averages. Quality 62: wide operating margins and strong free cash flow. Value 48: mixed.

Yield 1.6%P/E 30.4
81
Score
62
Q
48
V
70
M
Premium Grower
16
LALPATHLAB.NS
Dr. Lal PathLabs Limited
India · $3.2B

Quality 82: ROIC in the top 5% of its sector and strong free cash flow. Momentum 79: estimates revised up and near its 52-week high. Value 17: far above book value.

Yield 0.9%P/E 56.5
81
Score
82
Q
17
V
79
M
Premium GrowerDir. sell $7.3M
17
VIMTALABS.NS
Vimta Labs Limited
India · $220.3M

Quality 83: ROIC in the top 10% of its sector and high gross profitability. Momentum 60: above its moving averages. Value 36: little or no yield.

Yield 0.4%P/E 27.9
81
Score
83
Q
36
V
60
M
Premium Grower
18
QGEN
Qiagen N.V.
Netherlands · $10.4B

Momentum 70: outperforming the market over 6 months and above its moving averages. Quality 63: wide operating margins and strong free cash flow. Value 43: mixed.

Yield 0.7%P/E 27.2
79
Score
63
Q
43
V
70
M
Premium Grower
19
ILMN
Illumina, Inc.
United States · $40.7B

Quality 79: high return on equity and F-Score 8/9. Momentum 70: above its moving averages and outperforming the market over 6 months. Value 25: far above book value.

Yield —P/E 36.7
77
Score
79
Q
25
V
70
M
Premium GrowerDir. sell $610.8M
20
2395.T
Shin Nippon Biomedical Laboratories, Ltd.
Japan · $390.8M

Value 70: cheap on P/E and a high yield. Momentum 54: quarterly earnings growing but EPS deteriorating. Quality 51: high return on equity but a tight balance sheet.

Yield 3.4%P/E 10.6
77
Score
51
Q
70
V
54
M
Full House
21
IDXX
IDEXX Laboratories, Inc.
United States · $44.1B

Quality 84: ROIC in the top 5% of its sector and strong free cash flow. Momentum 69: near its 52-week high and outperforming the market over 6 months. Value 20: far above book value.

Yield —P/E 45.6
76
Score
84
Q
20
V
69
M
Premium GrowerDir. sell $28.6M
22
6127.HK
Joinn Laboratories(China)Co.,Ltd.
China · $2.2B

Momentum 74: estimates revised up and quarterly earnings growing. Quality 62: low debt and interest well covered. Value 37: expensive on EV/EBITDA.

Yield 0.6%P/E 13.7
76
Score
62
Q
37
V
74
M
Premium Grower
23
DIA.WA
Diagnostyka S.A.
Poland · $1.3B

Quality 75: high gross profitability and high return on equity. Value 56: a high yield but far above book value. Momentum 42: estimates cut.

Yield 2.9%P/E 19.9
76
Score
75
Q
56
V
42
M
Unloved Quality
24
LH
Labcorp Holdings Inc.
United States · $26.7B

Momentum 68: near its 52-week high and outperforming the market over 6 months. Quality 61: F-Score 8/9 and strong free cash flow. Value 44: mixed.

Yield 0.8%P/E 30.0
75
Score
61
Q
44
V
68
M
Premium GrowerDir. sell $4.0M
25
CDNA
CareDx, Inc.
United States · $3.6B

Momentum 83: outperforming the market over 6 months and above its moving averages. Quality 73: high gross profitability and high return on equity. Value 17: expensive on EV/EBITDA.

Yield —P/E 33.1
75
Score
73
Q
17
V
83
M
Premium GrowerDir. sell $16.7M

Ranked by MoatMap Score, the 0 to 100 score of Quality, Value and Momentum, among companies worth $200M or more that trade $1M or more a day, one line per company. Director dealings are director purchases and sales filed in the last 180 days, where MoatMap carries the market's filings.